1 “99.9% intrinsic AV conduction in 28/35 (80%) of patients of non-selected DDD patients” Anselme et al. First clinical results of AAIsafeR2, a new mode to prevent ventricular pacing. Heart Rhythm 2006; 2, supp 5; p4-99 (abs).
2. AAIsafeR in Symphony©DR 2550 pacemakers. CE mark granted in 2003. FDA approval in 2005.